Background. Colistin resistance is of concern since it is increasingly needed to treat infections caused by bacteria resistant to all other antibiotics and has been associated with poorer outcomes. Longitudinal data from in vivo series are sparse.
Polymyxin antibiotics such as colistin are increasingly relied upon as agents of last resort to treat infections caused by bacteria resistant to all other antibiotics [1, 2] .
Colistin's bactericidal activity is thought to occur through a detergent-like effect, in which the compound interacts with the hydrophilic lipid A component of lipopolysaccharide, disrupting the outer membrane and causing cell death [3] . A proposed alternative mechanism involves hydroxyl radical production [4] . Colistin resistance is concerning because there are no new antibiotics active against gram-negative bacteria are anticipated in the near future [5] , and colistin resistance has been associated with poorer clinical outcomes [6] .
Acinetobacter baumannii is an important nosocomial pathogen with a propensity to acquire resistance to multiple antibiotics [7] . Two mechanisms for colistin resistance in A. baumannii have been proposed. The first involves either mutations in the genes encoding lipid A biosynthesis-lpxA, lpxC, and lpxD [8] -or disruption of lpxA and lpxC expression by insertion sequence ISAba11 [9] . These alterations appear to cause a complete loss of lipopolysaccharide, resulting in decreased outer-membrane integrity and increased susceptibility to other antibiotics. The second mechanism is more common and involves mutations in pmrA and pmrB, leading to modification of bacterial lipopolysaccharide [10] [11] [12] . Unlike changes in lpxACD, mutations in pmrCAB do not result in increased susceptibility to other antimicrobials. It has been suggested that acquisition of colistin resistance is associated with reduced virulence and fitness, although this was based on the study of a single resistant clone obtained in vitro [13] .
Our objective was to perform an in-depth characterization of a longitudinal series of colistin-resistant A. baumannii isolates recovered during concurrent colistin therapy of severely warwounded patients. Our aims were to determine the genetic relatedness of the strains, to gain insight into the molecular mechanisms underlying the development of colistin resistance in vivo, and to screen for a putative association between acquired colistin resistance and change in baseline resistance to other antibiotics or fitness of the pathogen.
METHODS
This report is the result of a quality-improvement initiative authorized by the US Army Medical Command and respective institutional review boards to intensify infection-control measures.
Antibiotic susceptibility was determined according to Clinical Laboratory Standards Institute S100-M22 guidelines (Table 1 ) [15] . Primers (Supplementary Table 1) were designed using Primer Express, version 2.0 (Applied Biosystems), and validated using MIQE (Minimum Information for Publication of Quantitative Real-Time Polymerase Chain Reaction [PCR] Experiments) guidelines [17] . Pulsed-field gel electrophoresis (PFGE), optical genome mapping (OGM), in vitro growth rates and competition assays, sequencing of the pmrCAB operon, whole-genome sequencing, phylogenetic analysis, conventional and real-time PCR, and gene expression assays were performed as described in the Supplementary Methods.
RESULTS
Twenty-eight A. baumannii isolates (14 colistin-susceptible isolates and 14 colistin-resistant isolates) were recovered from 7 patients over 11 months (Table 1) . They were collected during infections that occurred in 2 clusters: 6 patients were in cluster 1, and 1 was in cluster 2. The second cluster occurred 3 months after the last isolate from the first cluster was recovered. All isolates were resistant to at least 1 drug from ≥4 antimicrobial classes and thus were classified as XDR isolates [18] . All isolates had low minimum inhibitory concentrations (MICs) of the investigational aminoglycoside arbekacin (Table 1) . Isolates were susceptible to minocycline but displayed varying susceptibility to tigecycline. Colistin resistance was not associated with altered susceptibility to other agents.
All patients in the study had sustained severe trauma in combat operations outside the United States, were <35 years old, were previously healthy without any comorbidities, and had been hospitalized in an intensive care unit or surgical ward. All patients had recently received antibiotics, but not colistin, for complicated infections during initial hospitalization in Afghanistan, transient hospitalization in Germany, and definitive hospitalization in the United States.
Clinical isolates were indistinguishable by PFGE ( Figure 1A ) and formed a separate cluster based on a 90% similarity cutoff when compared against 1500 A. baumannii collected from 24 geographically separated hospitals in the global Military Health System. OGM showed that the strains were >99% homologous and contained a number of chromosomal insertions, deletions, and rearrangements relative to A. baumannii reference strains AB0057, ACICU, and AYE ( Figure 1B ). The outbreak strain belonged to a rare multilocus sequence type (ST), ST94 [19, 20] .
All isolates had a pmrCAB operon whose sequence diverged from those of published A. baumannii pmrCAB operons (Supplementary Table 1 ). The absence of insertion sequences or transposons in the vicinity of the operon indicates that sequence divergence was due to evolutionary mechanisms rather than to acquisition of foreign DNA. The pmrB gene was identical to that of A. baumannii AB0057. However, PmrA and PmrC were more closely related to their Acinetobacter nosocomialis homologs than to A. baumannii proteins: 99% versus 98% identity and 97% versus 88% identity, respectively ( Table 2 ). The difference between 99% and 98%, although small, is significant: A. nosocomialis PmrA (99% identity) differs from PmrA1 by a single conservative amino acid difference, and A. baumannii PmrA (98% identity) has 2 conservative and 2 nonconservative amino acid changes relative to A. baumannii PmrA1. Consequently, we designated these genes pmrA1 and pmrC1. No complete or draft A. baumannii genome in GenBank had the pmrC1 allele.
Isolates had 2 additional pmrC-related genes, designated ethanolamine phosphotransferase A-1 (eptA-1) and A-2 (eptA-2), elsewhere in the chromosome. When calculated from the oriC, the pmrC1A1B operon was located from 795 449 to 799 147 bp; eptA-1 is located from 1 652 432 to 1 654 079 bp, and eptA-2 from 2 762 837 to 2 764 484 bp. These genes were more similar to the canonical pmrC gene than to pmrC1 ( Table 2) . Four of 11 A. baumannii strains with complete genome sequences had only pmrC; among these were AB0057 and AB307-0294, the isolates most closely related to the outbreak strain. Five strains had both pmrC and eptA-2, and 1, A. baumannii 1656-2, had pmrC, eptA-1, and eptA-2 (Supplementary Table 2 ). Of 116 draft A. baumannii genomes in the NCBI database (available at: http://www.ncbi.com), 20% possessed 2 eptA homologs in addition to pmrC, and another 4% contained ≥3 eptA homologs along with pmrC. It is noteworthy that in all strains from this series, eptA-1 and eptA-2 are associated with prophages. Phages with partial homology to Acinetobacter phage YMC/09/02/B1251 ABA BP [21] Abbreviations: ARB, arbekacin; MIC, minimum inhibitory concentration; MIN, minocycline; PMB, polymixin B; SAM, ampicillin-sulbactam; TGC, tigecycline. a Deidentified designation used to track isolates throughout the MRSN.
b Expressed in weeks after the first isolate was recovered from patient 1.
c Clinical site where the isolate was recovered.
d All strains were resistant to amikacin, gentamicin, imipenem, meropenem, tobramycin, and vancomycin. MICs of TGC, PMB, and MIN were determined in triplicate, using the Etest. SAM MICs were determined using 3 identification systems (see Methods). MICs of arbekacin were determined in triplicate by microbroth dilution as described elsewhere [14] . e "Yes" indicates treatment with colistin when the isolate was recovered.
f Based on MICs of colistin, as recommended by the Clinical and Laboratory Standards Institute [15] g Determined in quintuplicate, using Clinical and Laboratory Standards Institute guidelines [15] , with and without the addition of Tween 80 at a final concentration of 0.002% [16] .
We developed a duplex PCR assay that allows specific detection of pmrC1. The reaction generated 2 products: a 511-bp amplicon from pmrC1 and a 318-bp fragment derived from pmrC, eptA-1, or eptA-2 (Supplementary Figure 1) . Unexpectedly, among 110 clinical isolates of A. baumannii from our collection that differed with respect to pulse type, 12 tested positive for pmrC1 (data not shown). This indicates that pmrC1 is not a unique feature of ST94.
All 14 colistin-resistant isolates had nonsynonymous point mutations in the pmrA1 and/or pmrB genes when compared to the colistin-susceptible strains, amounting to 5 distinct mutations (Table 3) . Phylogenetic analysis was performed using Figure 1 . Pulsed-field gel electrophoresis (PFGE) and optical genome mapping profiles of selected strains. A, PFGE profiles showing the relatedness of the 27 clinical isolates and of Acinetobacter baumannii-reference strains. DNA was digested with ApaI and separated by gel electrophoresis. All strains were considered indistinguishable by use of a 90% cutoff. B, Optical maps and associated dendrogram of 12 strains compared with in silico optical maps of A. baumannii AB0057, AYE, and ACICU generated from GenBank sequences. Strain relatedness was calculated using the unweighted pair group method with arithmetic mean. Blue areas represent areas of alignment, compared with MRSN 3405, and white areas represent unaligned regions. Vertical black bars represent NcoI restriction cut sites. high-quality single-nucleotide polymorphisms (SNPs) only (ie, SNPs that were unambiguously present in all reads from the sequencing data. On the basis of this criterion, 18 high-quality SNPs were identified by comparing whole-genome sequences from 21 strains. Phylogenetic analysis was used to infer relatedness between isolates on the basis of high-quality SNP sets that include ( Figure 2A ) or exclude ( Figure 2B ) the 5 mutations identified in pmrA1 and pmrB. The analysis revealed that strains from clusters 1 and 2 were closely related, with MRSN (Multidrug-Resistant Organism Repository and Surveillance Network) 4611 representing an intermediary strain between both groups (Figure 2 ). Therefore, both clusters appear to be derived from a common colistin-susceptible progenitor strain despite having been isolated 3 months apart. (Table 3 ). The final sequenced strain from cluster 1, MRSN 4611, was collected from patient 6 twenty-two weeks after recovery of the first isolate. MRSN 4611 lies on a distinct branch of the phylogenetic tree ( Figure 2 ) and is the only strain to have the G788T mutation in pmrB. MRSN 4611 has 4 private SNPs as well as 2 variants shared by all strains from cluster 2. These data suggest that MRSN 4611 and the cluster 2 isolates had a common ancestor that arose from MRSN 3405 (Figure 2) . Cluster 2 composes a distinct phylogenetic branch because of 4 high-quality SNPs present in all members ( Figure 2 
Absolute transcript levels of pmrC, pmrC1, pmrA, pmrA1, pmrB, eptA-1, and eptA-2 were measured in 13 clinical isolates and pmrB averaged 10-fold higher than those from pmrC1 in colistin-susceptible strains (Figure 3 ), suggesting that, although these genes form an operon, there are additional regulatory Figure 3 . Transcription analysis of pmrA, pmrA1, pmrB, pmrC1, pmrC, eptA-1, and eptA-2. Normalized, log-transformed messenger RNA (mRNA) levels from pmrC1 (A), pmrC/eptA-1/eptA-2 (B), pmrA/A1 (C), and pmrB (D) from 5 colistin-susceptible clinical isolates, 8 colistin-resistant clinical isolates, and Acinetobacter baumannii AB0057. Data represent the average from 3 independent experiments; error bars represent 1 SD. One-way analysis of variance with the Tukey multiple-comparison correction was used to determine whether transcript levels from a gene differed among the strains. The results of statistical analysis in all multiple comparisons are tabulated below each graph. The hyphens indicate that the transcript levels did not differ significantly (P ≥ .05). *Primers for pmrC were complementary to eptA-1 and eptA-2. Data represent the combined transcript levels for eptA-1 and eptA-2 in ST94 strains and pmrC transcript levels in A. baumannii AB0057 only. Primers for pmrA cannot amplify from pmrA1 and vice versa. pmrA transcript levels in A. baumannii AB0057 have been added to the pmrA1 transcript data to facilitate direct comparisons.
mechanisms that exert a more subtle transcription control of each of the genes. This additional regulation is also observable in AB0057, where pmrA and pmrB transcripts were 4-8-fold more abundant than those of pmrC ( Figure 3 ). It is important to note that in the colistin-susceptible isolates, transcript levels of eptA-1 and eptA-2, unlike those of pmrC1, did not differ significantly from those of pmrA1 and pmrB, providing further evidence for additional regulatory elements controlling pmrC1A1B expression. Transcription of all genes was significantly higher in colistin-resistant strains, compared with their susceptible counterparts (Figure 3) , and was unaffected by the presence of colistin in the growth medium (data not shown).
Transcription from pmrC1 was up to 800-fold higher in colistin-resistant strains, compared with their colistin-susceptible counterparts. Expression of eptA-1 and eptA-2 was also significantly enhanced in resistant strains (Figure 3) . These results support the hypothesis that both eptA-1 and eptA-2 are at least partially controlled by the PmrAB 2-component regulatory system and may play a role in colistin resistance.
Whether the acquisition of antibiotic resistance affects fitness can be determined by measuring growth rates [22, 23] .
Growth rates of isolates from cluster 1, relative to that of susceptible MRSN 3405, began to decrease progressively at week 3, whereas the strains remained colistin susceptible. However, the greatest decrease (8% fitness loss) was observed for colistin-resistant strains isolated from patients 2, 4, 5, and 6 ( Figure 4) Figure 4B ). In all cases, the resistant isolate displayed a marked competitive disadvantage. Figure 4 . Evaluation of fitness. A, Growth rates of 13 colistin-susceptible strains (gray bars) and 14 colistin-resistant strains (black bars) were determined at the beginning of the exponential phase. The relative growth rate represents the ratio of growth of every strain from patient 1 to 6 to that of MRSN (Multidrug-Resistant Organism Repository and Surveillance Network) 3405 or from patient 7 to MRSN 5540 (taken as 1). The values are the means for 3 cultures from 5 independent experiments with error deviations. *Significant difference P < .01 of the mean value. B, For competition, colistin susceptible strains (black dots) were cocultured at a 1:1 ratio with resistant isolates (red dots) over 5-6 cycles. Log 10 colony-forming units (CFU) of the resistant and susceptible populations at the end of each transfer (approximately 10 generations) were plotted against the number of generations. The selection coefficient(s) was calculated as the slope of the linear regression model ln(CI)/ln(d), where CI is the CFU ratio of the resistant and susceptible population at t 1 divided by the same ratio at t 0 , and d is the dilution factor. The data represent the mean number of CFU (±SD) in 2 independent cultures from 2-3 independent experiments.
DISCUSSION
Active surveillance of multidrug-resistant organisms provided the opportunity to study the evolution of colistin resistance in a longitudinal series of A. baumannii isolates collected from patients undergoing antibiotic therapy. The A. baumannii outbreak strain was unrelated to known pulse types of A. baumannii and belonged to the rare multilocus sequence type ST94, which has been reported only twice to date [19, 20] . Whole-genome phylogenetic analysis suggests that all isolates were closely related and represent the expansion of a single colistin-susceptible strain.
Colistin had been used since 2003 at the facility where this outbreak occurred. Based on a query of the database of microbiology results, there were no instances of colistin-resistant A. baumannii isolated from clinical infections from 2003 to 2012. Furthermore, there are no published reports of colistin-resistant Acinetobacter within the Military Health System during this period. While it is tempting to suggest that the A. baumannii strain described herein has a propensity to develop colistin resistance more rapidly than strains carrying the canonical pmrCAB operon, we were unable to demonstrate this in vitro (data not shown). However, it is noteworthy that the compound used for in vitro testing (colistin sulfate) differs from the prodrugs used in vivo (colistin methanesulfonate or colistimethate compounds) [24] . Various factors affect the rate and amount of prodrug conversion in the body. Therefore, the results of in vitro exposure assays may not be generalizable to an organism that encounters evolving colistin concentrations in vivo.
Isolates carried a novel allele of the pmrCAB gene cluster, designated pmrC1A1B. PmrB was identical to pmrB in A. baumannii AB0057, but both pmrC1 and pmrA1 contained nonsynonymous mutations, compared with the pmrC and pmrA genes from reference strains.
An analysis of complete and draft genome sequences of A. baumannii demonstrated that pmrC1 is unique to our isolates. The absence of transposable elements in the surrounding region argues against horizontal transfer and suggests that this allele likely diverged from the majority allele through evolutionary pressure. In a random sample of 110 A. baumannii clinical isolates collected by our surveillance network, >10% carried pmrC1. Although this result indicates that pmrC1 is relatively common in A. baumannii, it is important to note that current biochemical testing cannot distinguish between A. baumannii, A. nosocomialis, and Acinetobacter pittii. Studies suggest that the latter 2 strains can account for 10%-40% of all clinical isolates identified as A. baumannii [25] [26] [27] , and these pmrC1-carrying isolates may belong to these species.
All colistin-resistant isolates carried mutations in the pmrC1A1B operon. Four mutations were identified in PmrB (S17R, T232I, R263L, and Y116H), and 1 was identified in PmrA1 (E8D). The PmrB changes have not yet been described (although R263P and R263C were reported by Arroyo et al [11] ).
The S17R and Y116H PmrB substitutions occurred outside the histidine-kinase domain and may influence the interactions between PmrA and PmrB. Mutations in this region of the protein, including S119T, S14L, and T13N, have been identified in colistin-resistant strains [10] [11] [12] . The E8D substitution in PmrA1 is identical to a PmrA mutation in a colistin-resistant A. baumannii clinical isolate [28] .
The data suggest that multiple independent colistin resistant clones arose from the initial susceptible strain, represented by MRSN 3405, during therapy. Isolates from patients 1, 2, and 3 were closely related, based on high-quality SNPs, but acquisition of colistin resistance occurred through different mutations. In contrast, MRSN 4611 from patient 6 showed evolutionary divergence from MRSN 3405. MRSN 4611 shares 2 highquality SNPs that are found in all cluster 2 isolates, suggesting that this strain and the isolates from the second outbreak had a common progenitor descended from the founder A. baumannii clone. Because the earliest isolates from cluster 2 are colistin susceptible, the parental strain from cluster 1 may have reverted to colistin susceptibility in the absence of selective pressure before it reemerged 3 months later in patient 7. When this patient underwent colistin therapy, A. baumannii became drug resistant via new pmrA1 and pmrB mutations. It should be noted that the 18 SNPs we used for phylogenetic analysis may not represent the complete set of genomic differences among the outbreak strains. We are currently producing a finished genome of the initial isolate, which will serve as reference sequence for identifying all SNPs, indels, and rearrangements that arose during the in vivo evolution of the outbreak strain.
Importantly, because bacteria from clinical samples are cultured from single, pure colonies, subpopulations of Acinetobacter with various mutations in pmrA and pmrB could coexist in the same patient and go undetected. We were able to identify multiple mutations in the outbreak isolates by collecting serial samples from patients over an extended period.
In addition to the variant pmrC1 gene, the outbreak strain had 2 pmrC homologs, eptA-1 and eptA-2. These genes have >95% identity with canonical pmrC from A. baumannii AB0057 but <90% identity with pmrC1. Prophages are located in the vicinity of both genes in all strains, and eptA-1 lies 900 bp upstream from a putative integrase gene. This provides tantalizing evidence that both genes may have been horizontally acquired or duplicated within the ancestral strain. eptA-1 and eptA-2 showed significantly enhanced expression in colistinresistant strains, but because the real-time primers cannot discriminate between the genes, expression data presumably reflect transcription of both genes. These data support the hypothesis by Arroyo et al that additional copies of pmrC might be found in 2 of the clinical isolates from their study, based on the observation that, compared with the reference strain, both strains showed approximately 6-fold higher transcription from pmrC when pmrB was knocked out [11] .
A comprehensive search for these genes in full and complete draft genomes of A. baumannii demonstrated that 6 of the 11 complete genome sequences contain eptA-2 and that 1 also contains eptA-1. Furthermore, examination of 116 draft genomes shows that approximately 20% of A. baumannii may possess, in addition to pmrC, 2 eptA homologues and that 4% might harbor ≥3. The existence of the third or fourth eptArelated gene is based on an incomplete gene sequence, so uncertainties remain. The potential contribution of EptA-1 and EptA-2 to colistin resistance needs further investigation because the evidence we provide here is circumstantial. Unraveling the role of these proteins may provide a greater understanding of the role of phosphoethanolamine modification of lipid A in polymyxin resistance.
Colistin-resistant clinical isolates displayed variable levels of fitness loss, with a moderate reduction in growth rates associated with resistance in the initially isolated strains. This might have allowed the resistant phenotype to emerge. However, in later strains isolated from the same patient, the cost of resistance was high. Competition was performed over 5 cycles of growth and with stably resistant clones, demonstrating a clear competitive disadvantage associated with this type of colistin resistance. There was no evidence to support the notion that colistin-resistant isolates suffered compensatory mutations that increased virulence or fitness [28, 29] . On the contrary, there was increasing loss in fitness in successive colistin-resistant strains. Furthermore, colistin-resistant strains were recovered only once from patients 2, 3, 4, 5, and 6, suggesting that such strains were unable to colonize or invade these patients.
Unlike previous reports [29] [30] [31] , colistin resistance in these isolates was not associated with increased susceptibility to other antibiotics, including vancomycin (sometime referred to as the seesaw effect) [32] . All colistin-resistant A. baumannii infections were successfully treated with extended infusion of various combinations of tigecycline, minocycline, and/or colistin, and/or high-dose carbapenems. The isolates were also resistant to all aminoglycosides currently available in the United States but had low MICs of arbekacin, an aminoglycoside used in Japan to treat methicillin-resistant Staphylococcus aureus that shows promising activity against multidrug resistant gramnegative bacteria [33] .
The relationship between our surveillance network and physicians, microbiologists, and infection preventionists enables collection of all organisms isolated from a patient. Typically, subsequent isolates are referred to the first or an earlier specimen from the same anatomic location. In one patient, detection of the emergence of colistin resistance would have been delayed using this customary referral approach. Following identification of colistin resistance, infection-control measures were further intensified. However, for combating antibiotic resistance due to mutational events, reducing or eliminating selection pressure is just as important as intensification of transmission-based precautions.
In summary, our findings underscore the genomic fluidity of A. baumannii and highlight the value of combining active surveillance with translational research. This capability permits longitudinal surveillance of clinical isolates and lends insight into their adaptive evolution under antibiotic pressure. Finally, our findings support calls for better antibiotic stewardship because colistin, an antibiotic that until recently had fallen into disuse owing to nephrotoxicity, is now a therapeutic mainstay in patients for whom there are no alternatives.
NUCLEOTIDE SEQUENCES
Sequences of wild-type and mutant alleles of the pmrC1A1B operon have been submitted to GenBank under accession numbers KC009850-KC009855. The eptA-1 and eptA-2 sequences were submitted as accession numbers KC161249 and KC161248, respectively. The corresponding genetic context of eptA-1 and eptA-2 have been submitted separately to GenBank as accession numbers (KC700024, eptA-1 context; KC700023, eptA-2 context).
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